Exelixis (EXEL)
(Delayed Data from NSDQ)
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.97 USD
-0.20 (-0.74%)
Updated Aug 9, 2024 04:00 PM ET
After-Market: $26.97 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
B Value B Growth A Momentum A VGM
Zacks News
Bristol-Myers (BMY) Misses on Q1 Earnings, Opdivo Sales Decline
by Zacks Equity Research
Bristol-Myers (BMY) misses earnings and sales estimates in the first quarter on weak Opdivo sales.
Bristol Myers' (BMY) Opdivo Combo Gets EU Nod for First-Line RCC
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Opdivo in combination with Cabometyx for first-line treatment of advanced renal cell carcinoma.
Exelixis' (EXEL) IND for Oncology Candidate Accepted by FDA
by Zacks Equity Research
The FDA accepts Exelixis' (EXEL) IND for XB002 in patients with advanced solid tumors and a phase I study is expected to start in the second quarter.
Exelixis (EXEL) Partner Gets EC Nod for Cabometyx + Opdivo
by Zacks Equity Research
Exelixis' (EXEL) partner Ipsen secures an approval from the regulatory body in Europe for the combination of Cabomteyx and Opdivo to treat first-line RCC.
Exelixis (EXEL) Inks Collaboration Deal to Test XL092 Combo in UC
by Zacks Equity Research
Exelixis (EXEL) signs a collaboration and supply agreement with Merck KGaA and Pfizer to investigate XL092 in combination with Bavencio for treating various forms of urothelial carcinoma.
AVEO Collaborates with Bristol Myers to Conduct Combo Study
by Zacks Equity Research
AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.
Why Is Exelixis (EXEL) Up 3.4% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Exelixis' (EXEL) Q4 Earnings Surpass Estimates, Sales Miss
by Zacks Equity Research
Exelixis (EXEL) beats on earnings in the fourth quarter but misses on revenues.
Exelixis (EXEL) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of 200.00% and -0.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Bristol Myers (BMY) Gets European Commission Nod for Inrebic
by Zacks Equity Research
The European Commission approves Bristol Myers' (BMY) Inrebic for the treatment of adult patients with newly diagnosed and previously treated myelofibrosis.
Exelixis (EXEL) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on pipeline and guidance updates when Exelixis (EXEL) reports fourth-quarter 2020 results.
Bristol-Myers (BMY) Q4 Earnings Beat, 2021 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the fourth quarter on strength of Revlimid and Eliquis.
Earnings Preview: Exelixis (EXEL) Q4 Earnings Expected to Decline
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in the Cards for Bristol-Myers' (BMY) Q4 Earnings?
by Zacks Equity Research
Investors will focus on regular top and bottom-line numbers along with key pipeline updates when Bristol-Myers (BMY) reports fourth-quarter 2020 results.
Biotech Stock Roundup: Coronavirus Updates From REGN, MRNA, & Other Updates
by Zacks Equity Research
The biotech sector was in focus last week with regulatory and pipeline updates from quite a few companies like Regeneron (REGN), Moderna (MRNA) and Exelixis (EXEL).
Exelixis (EXEL) Wins FDA Nod for Cabometyx + Opdivo in RCC
by Zacks Equity Research
Exelixis (EXEL) obtains FDA approval for Cabometyx in combination with immuno-oncology drug, Opdivo, for the first-line treatment of patients with advanced kidney cancer.
Exelixis (EXEL) Reports Preliminary Q4 Results, Business Updates
by Zacks Equity Research
Exelixis (EXEL) provides preliminary results for the fourth quarter and 2020 along with the annual guidance for 2021. It also throws light on anticipated milestones for 2021.
Calithera (CALA) Plunges as CANTANA Study on Telaglenastat Fails
by Zacks Equity Research
Calithera (CALA) tanks as CANTATA study on its lead pipeline candidate, telaglenastat, did not achieve its primary goal for RCC.
Exelixis (EXEL) Posts Positive Data From Thyroid Cancer Study
by Zacks Equity Research
Exelixis' (EXEL) cabozantinib meets the co-primary endpoint in the late-stage study for the treatment of differentiated thyroid cancer following anti-VEGFR therapy.
Exelixis (EXEL) In-Licenses Aurigene's Compound, Files IND
by Zacks Equity Research
Exelixis (EXEL) exercises an option to in-license Aurigene's novel CDK7 inhibitor and submits an IND to the FDA for evaluating the candidate in a phase I study.
Why Is Exelixis (EXEL) Down 14.4% Since Last Earnings Report?
by Zacks Equity Research
Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
New Strong Sell Stocks for November 11th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Exelixis (EXEL) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Exelixis (EXEL) delivered earnings and revenue surprises of -100.00% and 7.05%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Exelixis (EXEL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Exelixis (EXEL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.